Marksans Pharma Limited (NSE:MARKSANS)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceuticals	29.51B	26.23B	21.77B	18.52B	14.91B
Pharmaceuticals Growth	12.51%	20.46%	17.56%	24.23%	8.33%
Total	29.51B	26.23B	21.77B	18.52B	14.91B
Total Growth	12.51%	20.46%	17.56%	24.23%	8.33%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United States and North America	12.37B	9.18B	7.75B	6.35B
United States and North America Growth	34.68%	18.53%	21.98%	8.47%
Europe and The United Kingdom	10.30B	9.43B	7.68B	6.09B
Europe and The United Kingdom Growth	9.20%	22.85%	26.02%	4.66%
Australia and New Zealand	2.53B	2.19B	2.09B	1.80B
Australia and New Zealand Growth	15.54%	4.45%	16.51%	22.89%
Rest of World	1.04B	974.49M	1.00B	554.80M
Rest of World Growth	6.37%	-2.96%	81.00%	-10.95%
India	-	-	-	113.79M
Total	26.23B	21.77B	18.52B	14.91B
Total Growth	20.46%	17.56%	24.23%	8.34%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 12, 2026

Data Sources Report a data error